CRL vs. TEM: Charles River Laboratories vs. Tempus AI Stock Comparison
How do Charles River Laboratories (CRL) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
Charles River Laboratories (CRL) carries decades of public-market history since June 23, 2000, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the CRL side.
| Profile Item | CRL | TEM |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Tempus AI Inc Class A Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 16.17 billion USD | 13.87 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 23, 2000 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | TEM |
|---|---|---|
| Total Return (1Y) | 110.83% | 16.25% |
| Total Return (3Y, Annualized) | 27.87% | -- |
| Total Return (5Y, Annualized) | -1.57% | -- |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | TEM |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 76.08% |
| Beta (5Y) | 1.33 | 3.34 |
| Max Drawdown (5Y) | -74.73% | -59.76% |
| Avg. Volume (3M) | 1.05M | 7.20M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | TEM |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 0.16 |
| Sortino Ratio (1Y) | 3.58 | 0.26 |
Profitability
ROE (TTM)
Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Charles River Laboratories (CRL) reports 23.42%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CRL | TEM |
|---|---|---|
| ROE (TTM) | 1.27% | -37.55% |
| ROA (TTM) | 4.74% | -7.36% |
| Net Margin (TTM) | 1.01% | -12.54% |
| Operating Margin (TTM) | 23.42% | -13.82% |
| Gross Margin (TTM) | 35.10% | 64.46% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Charles River Laboratories (CRL) at -0.85% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.
Growth Metrics
| Metric | CRL | TEM |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | 83.41% |
| Revenue Growth (3Y CAGR) | 0.33% | 58.29% |
| EPS Growth (YoY) | -1,555.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Charles River Laboratories (CRL) at 0.87 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | TEM |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | 2.61 |
| Debt / Equity (MRQ) | 0.87 | 2.86 |
| Net Debt / EBITDA | 2.92 | -- |
Dividends
Dividend Yield (TTM)
Neither Charles River Laboratories (CRL) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Charles River Laboratories (CRL) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
P/S Ratio (TTM)
On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Charles River Laboratories (CRL) at 5.01 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CRL | TEM |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | -- |
| P/S Ratio (TTM) | 4.07 | 9.19 |
| P/B Ratio (MRQ) | 5.01 | 27.66 |
| Free Cash Flow Yield (TTM) | 2.74% | 0.30% |